TL;DR
This study identifies the deubiquitinating enzyme USP28 as a key driver of non-small cell lung cancer (NSCLC) growth. High levels of USP28 correlate with poor patient survival, and its overexpression promotes tumor cell proliferation while its downregulation induces apoptosis, suggesting USP28 is a promising therapeutic target.
What Problem Does This Paper Address?
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths, and understanding its underlying pathogenesis is crucial for developing effective therapies. While deubiquitinating enzymes (DUBs) are known to play roles in various cellular processes, the specific function of USP28 in NSCLC remained largely unknown. This paper aims to elucidate the role of USP28 in NSCLC, investigating its impact on tumor growth, patient prognosis, and potential regulatory mechanisms.
Methods
The researchers employed a multi-pronged approach to investigate USP28's role in NSCLC:
- Expression Analysis: They quantified USP28 mRNA levels using quantitative real-time PCR (qRT-PCR) in both NSCLC cell lines and patient tissues, comparing them to normal controls. Immunohistochemistry (IHC) was used to assess USP28 protein expression in tumor and adjacent normal tissues.
- Functional Assays:
- Cell Proliferation: The MTT assay was used to measure the impact of USP28 manipulation on NSCLC cell growth.
- Apoptosis: Flow cytometry (FACS) analysis with Annexin V-FITC and propidium iodide was employed to assess the rate of programmed cell death.
- Genetic Manipulation:
- Overexpression: USP28 was overexpressed in NSCLC cells using a pcDNA3.1-USP28 plasmid to study its pro-tumorigenic effects.
- Knockdown: Small interfering RNA (siRNA) targeting USP28 was used to downregulate its expression and observe the consequences.
- MicroRNA Interaction:
- Prediction: Bioinformatic algorithms (TargetScanHuman) were used to predict microRNAs (miRNAs) that might target USP28.
- Validation: A dual-luciferase reporter assay system was employed to confirm the interaction between a predicted miRNA (miR-4295) and the 3' untranslated region (3'UTR) of USP28 mRNA. This involved transfecting cells with reporter plasmids containing either the wild-type or a mutated USP28 3'UTR along with the miRNA of interest.
Datasets
- Patient Samples: Surgical specimens from 70 NSCLC patients and matched normal control adjacent tissues were collected.
- Cell Lines: Human normal lung fibroblast cell line MRC-5, and human NSCLC cell lines (SPC-A-1, LTEP-A-2, SK-MES-1, A549, and H1299) were used. The HEK293 cell line was used for miRNA validation experiments.
Key Insights and Ideas
- USP28 as a Prognostic Marker: The study strongly suggests that USP28 expression levels (both mRNA and protein) are directly correlated with patient survival. Higher USP28 levels are associated with a poorer prognosis, making it a potential biomarker for NSCLC.
- USP28 Drives Proliferation: Overexpressing USP28 significantly enhances the proliferation of NSCLC cells, while reducing its levels has the opposite effect, highlighting its critical role in tumor growth.
- USP28 Induces Apoptosis: Conversely, downregulating USP28 expression through siRNA treatment leads to increased apoptosis in NSCLC cells, further emphasizing its pro-survival role in cancer.
- miR-4295 as a Regulator: The research identifies miR-4295 as a novel miRNA that directly targets USP28. This suggests a regulatory axis where miR-4295 might act as a tumor suppressor by downregulating USP28.
Key Results
- Elevated USP28 in NSCLC: USP28 mRNA and protein levels were significantly higher in NSCLC tissues and cell lines compared to normal controls.
- Survival Correlation: Kaplan-Meier analysis revealed that patients with high USP28 expression had significantly reduced overall survival rates. For instance, in one analysis, USP28 high expression (n=53) was associated with worse survival compared to USP28 low expression (n=17).
- USP28 Promotes Growth: Overexpression of USP28 in A549 and H1299 cells led to increased proliferation, as measured by MTT assay.
- USP28 Inhibition Induces Apoptosis: Downregulation of USP28 using siRNA in A549 and H1299 cells resulted in a significant increase in apoptosis rates.
- miR-4295 Targets USP28: The dual-luciferase reporter assay demonstrated that miR-4295 directly binds to the 3'UTR of USP28, leading to reduced luciferase activity. This interaction was abolished when the binding site in the USP28 3'UTR was mutated.
Limitations and Future Work
- Minor Effect Size: The authors acknowledge that the observed effects of USP28 on proliferation and apoptosis were relatively minor (4-8% change). However, they hypothesize that these small changes can lead to significant differences in patient survival over time due to the exponential nature of cell proliferation in vivo.
- Mechanism of Action: While the study establishes USP28's role and its regulation by miR-4295, the precise molecular pathways through which USP28 exerts its pro-tumorigenic effects in NSCLC require further investigation. The authors mention that USP28 is involved in various pathways, including MYC stability and DNA damage response, and suggest further research to compare gene profiles.
- miR-4295's Role in Survival: The study proposes that miR-4295 might be related to NSCLC patient survival, but this aspect requires further investigation.
- Therapeutic Target Validation: While USP28 is proposed as a promising therapeutic target, further studies are needed to explore the efficacy and safety of targeting USP28 in NSCLC treatment.
Summary updated